< Previous | Contents | Next >

RUSSIAN FEDERATION


image

(19) RU (11) 2 732 924(13) C2

(51) Int. Cl.

A61K 39/395 (2006.01)

C07K 16/28 (2006.01)

C12Q 1/68 (2006.01)

C12N 15/09 (2006.01)

C12Q 1/02 (2006.01)

C12N 5/00 (2006.01)

FEDERAL SERVICE C12P 21/08 (2006.01)

FOR INTELLECTUAL PROPERTY

(12) ABSTRACT OF INVENTION

image

(52) CPC

A61K 39/39558 (2020.01); C07K 16/28 (2020.01); C07K 16/18 (2020.01); A61K 51/10 (2020.01); C07K

R U

R U

R U

2 7 3 2 9 2 4

2 7 3 2 9 2 4

2 7 3 2 9 2 4

16/2818 (2020.01); A61K 2039/505 (2020.01); C07K 16/468 (2020.01)


(21)(22) Application: 2016133899, 18.08.2016

(72) Inventor(s):

(24) Effective date for property rights:

02.05.2006

KORMAN Alan Dzh. (US), SRINIVASAN Mokhan (US),

VAN Chanyuj (US),

Registration date:

24.09.2020

Priority:

SELBI Mark Dzh. (US), CHEN Bin (US),

KARDARELLI Zhozefin M. (US)

(30) Convention priority:

(73) Proprietor(s):

09.05.2005 US 60/679,466;

ONO FARMASYUTIKAL KO., LTD. (JP),

21.11.2005 US 60/728,434;

E.R. Skvibb end Sanz, El.El.Si. (US)

08.12.2005 US 60/748,919


Number and date of priority of the initial application,


from which the given application is allocated:


2013133714 09.05.2005


(43) Application published: 22.02.2018 Bull. № 6


(45) Date of publication: 24.09.2020 Bull. № 27


Mail address:


119019, Moskva, Gogolevskij b-r, 11, etazh 3,


"Gouling VLG (Interneshnl) Ink.", Karpenko


Oksana Yurevna


C 2

C 2

C 2

2 7 3 2 9 2 4

2 7 3 2 9 2 4

2 7 3 2 9 2 4

C 2

C 2

C 2

(54) HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS

(57) Abstract:

FIELD: biotechnology.

R U

R U

R U

SUBSTANCE: described is a method of treating an infectious disease in a subject, a method for modifying an immune response to an infectious agent in a subject and a method of activating T-cell responses to an infectious agent in a subject. Above methods are implemented with participation of an antibody or its antigen-binding part containing: Heavy chain CDR1 containing amino acids, having sequence given in SEQ ID NO: 15–21; CDR2 heavy chain containing amino acids having a sequence given in SEQ ID NO: 22–28;

CDR3 heavy chain containing amino acids, having sequence given in SEQ ID NO: 29–35; CDR1 light chain containing amino acids having the sequence given in SEQ ID NO: 36–42; Light chain CDR2 containing amino acids, having sequence given in SEQ ID NO: 43–49; and light chain CDR3 containing amino acids having the sequence given in SEQ ID NO: 50–56.

EFFECT: invention extends the range of products for treating infectious diseases.

19 cl, 54 dwg, 7 tbl, 24 ex


  

 

< Previous | Contents | Next >